Tempus AI (NASDAQ:TEM - Get Free Report) was downgraded by research analysts at Stifel Nicolaus from a "buy" rating to a "hold" rating in a research note issued to investors on Monday, MarketBeat.com reports. They presently have a $65.00 target price on the stock, up from their previous target price of $45.00. Stifel Nicolaus' target price indicates a potential downside of 9.56% from the company's previous close.
Other analysts have also issued research reports about the company. Loop Capital increased their price objective on Tempus AI from $48.00 to $57.00 and gave the company a "buy" rating in a research note on Tuesday, October 15th. Piper Sandler started coverage on shares of Tempus AI in a report on Monday, August 12th. They issued a "neutral" rating and a $40.00 price target on the stock. Bank of America downgraded shares of Tempus AI from a "buy" rating to a "neutral" rating and upped their price objective for the company from $45.00 to $60.00 in a research note on Wednesday, October 2nd. Needham & Company LLC reissued a "buy" rating and issued a $47.00 target price on shares of Tempus AI in a research note on Wednesday, August 7th. Finally, JPMorgan Chase & Co. upped their price target on Tempus AI from $42.00 to $47.00 and gave the company an "overweight" rating in a research report on Wednesday, August 7th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $50.89.
View Our Latest Report on TEM
Tempus AI Stock Down 2.6 %
NASDAQ TEM traded down $1.90 on Monday, reaching $71.87. 1,116,818 shares of the company's stock traded hands, compared to its average volume of 1,173,021. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 3.52. Tempus AI has a 12 month low of $22.89 and a 12 month high of $77.00. The stock has a 50-day moving average price of $50.22.
Institutional Trading of Tempus AI
Several hedge funds have recently modified their holdings of the company. NEA Management Company LLC purchased a new stake in Tempus AI during the 2nd quarter valued at $160,048,000. Novo Holdings A S bought a new position in Tempus AI during the second quarter valued at $142,605,000. Revolution Growth Management Company Inc. purchased a new stake in shares of Tempus AI in the second quarter valued at $128,133,000. ARK Investment Management LLC lifted its holdings in shares of Tempus AI by 355.0% in the 3rd quarter. ARK Investment Management LLC now owns 2,378,157 shares of the company's stock worth $134,604,000 after acquiring an additional 1,855,459 shares during the last quarter. Finally, Alphabet Inc. purchased a new position in shares of Tempus AI during the 2nd quarter worth about $54,289,000.
About Tempus AI
(
Get Free Report)
Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.
See Also
Before you consider Tempus AI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tempus AI wasn't on the list.
While Tempus AI currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
